Danaher Co. (NYSE:DHR) Shares Sold by Connable Office Inc.

Connable Office Inc. lessened its holdings in shares of Danaher Co. (NYSE:DHR) by 11.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 12,504 shares of the conglomerate’s stock after selling 1,626 shares during the period. Connable Office Inc.’s holdings in Danaher were worth $2,870,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of DHR. Heck Capital Advisors LLC acquired a new stake in Danaher in the fourth quarter valued at $27,000. Decker Retirement Planning Inc. acquired a new stake in Danaher in the fourth quarter valued at $31,000. Golden State Wealth Management LLC acquired a new stake in Danaher in the fourth quarter valued at $31,000. Strategic Financial Concepts LLC acquired a new stake in Danaher in the fourth quarter valued at $31,000. Finally, Pineridge Advisors LLC grew its holdings in Danaher by 63.3% in the fourth quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock valued at $34,000 after purchasing an additional 57 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Performance

NYSE DHR opened at $207.73 on Friday. The business’s 50-day moving average price is $224.58 and its 200 day moving average price is $245.09. The company has a market capitalization of $148.47 billion, a PE ratio of 39.34, a price-to-earnings-growth ratio of 2.66 and a beta of 0.83. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. Danaher Co. has a twelve month low of $196.80 and a twelve month high of $281.70.

Danaher (NYSE:DHR) last released its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period in the prior year, the business posted $2.09 EPS. On average, research analysts predict that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.62%. This is an increase from Danaher’s previous quarterly dividend of $0.27. The ex-dividend date is Friday, March 28th. Danaher’s dividend payout ratio (DPR) is 24.24%.

Insider Transactions at Danaher

In other news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 11.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on DHR shares. Guggenheim started coverage on Danaher in a report on Thursday, December 19th. They issued a “buy” rating and a $275.00 target price on the stock. Wells Fargo & Company lowered their target price on Danaher from $280.00 to $240.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th. Jefferies Financial Group lowered their target price on Danaher from $285.00 to $260.00 and set a “buy” rating on the stock in a report on Wednesday, January 29th. Scotiabank initiated coverage on Danaher in a research note on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price objective on the stock. Finally, Bank of America raised Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective on the stock in a research note on Friday, December 13th. Seven equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $278.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.